Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | B2M negative |
| Therapy | Nivolumab |
| Indication/Tumor Type | melanoma |
| Response Type | predicted - resistant |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| B2M negative | melanoma | predicted - resistant | Nivolumab | Case Reports/Case Series | Actionable | In a clinical case study, loss of B2m protein expression was identified during and after disease progression in a melanoma patient harboring B2M loss of heterozygosity (LOH), whose disease briefly responded to Opdivo (nivolumab) treatment (PMID: 29070816). | 29070816 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (29070816) | Resistance to checkpoint blockade therapy through inactivation of antigen presentation. | Full reference... |